Stem cell

Cimeio Therapeutics Presents Data for its CD45 Universal Heme ADC at ASH

Retrieved on: 
Tuesday, December 12, 2023
Oncology, Health, Stem Cells, General Health, Pharmaceutical, Biotechnology, American Society of Hematology, Therapy, ASH, ADC, Leukemia, Stem cell, Mouse, Patient, Dana–Farber Cancer Institute, System, CD33, Bone marrow, Harvard Medical School, CD45, AML, Society, Cell, Haematopoietic system, Vaccine, Medicine

Cimeio Therapeutics, the leading biotechnology company in the field of epitope shielding, presented data for its CD45 and CD33 programs during this weekend’s American Society of Hematology (ASH) meeting in San Diego.

Key Points: 
  • Cimeio Therapeutics, the leading biotechnology company in the field of epitope shielding, presented data for its CD45 and CD33 programs during this weekend’s American Society of Hematology (ASH) meeting in San Diego.
  • The two studies provide further evidence that epitope editing allows for the development of powerful immunotherapies that would not be safe to administer without first protecting healthy cells.
  • After just two doses of CIM053-ADC, all mice were cancer-free while the healthy hematopoietic cells were unaffected.
  • This study demonstrates the potential of CD45-targeted ADC therapy for patients with hematologic malignancies.

Healthspan for All! Healthspan Action Coalition Expands to 120 Organizations Across the Spectrum of Advocacy, Science, Technology, Industry, Funding, and Media

Retrieved on: 
Wednesday, December 13, 2023
World Health Organization, Life expectancy, B cell, Regenerative medicine, Longevity, Research, SAN, Policy, Gene editing, Organization, HSAC, Acceleration, Collection, Disease, ICD, Stem cell, Life, Science, Tissue engineering, Movement, Ageing, Death, AI, Robotics, SCI, Medical device

SAN FRANCISCO, Calif. and WEST PALM BEACH, Fla., Dec. 13, 2023 /PRNewswire-PRWeb/ -- The nonprofit Healthspan Action Coalition (HSAC), in its first year of operations, has already assembled 120 organizations under the banner of "Healthspan." This societal movement recognizes that with new science aided by the convergence of new technologies, a healthy lifespan should be available for all populations, regardless of ethnicity and economic status.

Key Points: 
  • SAN FRANCISCO, Calif. and WEST PALM BEACH, Fla., Dec. 13, 2023 /PRNewswire-PRWeb/ -- The nonprofit Healthspan Action Coalition (HSAC), in its first year of operations, has already assembled 120 organizations under the banner of "Healthspan."
  • This proposition is buoyed by the World Health Organization, which in 2022 provided an ICD code recognizing that aging is a treatable medical condition.
  • But there are exciting developments in bona fide longevity and healthspan research, and true progress is within reach."
  • To learn more about our activities, receive our newsletter or join the coalition, visit www.healthspanaction.org .

Stem Cell Therapy Market Worth $615 Million | MarketsandMarkets

Retrieved on: 
Tuesday, December 12, 2023
Microsoft Exchange Server, DSM-IV codes, Research, Prevalence, Takeda Pharmaceutical Company, IND, RTI Surgical, Investment, NuVasive, Market development, Patient, ALS, PVT, COVID-19, Stem cell, Master of ceremonies, US FDA, Technical, Cancer, Pulse, RESEARCH, Growth, Embryonic stem cell, Ethics, Adipose tissue, Silk, Veterinary medicine, Pharmaceutical industry

The global stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources.

Key Points: 
  • The global stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources.
  • Stem Cell Therapy Market Dynamics:
    Key Market Players of Stem Cell Therapy Industry:
    The stem cell therapy market is competitive, with a small number of players competing for market shares.
  • Stem Cell Therapy Market - Key Benefits of Buying the Report:
    The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy market and its subsegments.
  • The report provides insights on the following pointers:
    Analysis of key drivers (Increased funding for stem cell research, rise in collabrations and partnerships is likley to uplift the market growth, Increasing clinical trials for stem cell based-therapies), restraints ( Ethical concerns related to embryonic stem cells, high cost of cell-based research), opportunities (The emergence of iPSCs as an alternative to ESCs, growing demand for stem cell and gene therapy) and challenges (Technical limitations) are influencing the growth of stem cell therapy market.

Stem Cell Therapy Market Worth $615 Million | MarketsandMarkets

Retrieved on: 
Tuesday, December 12, 2023
Microsoft Exchange Server, DSM-IV codes, Research, Prevalence, Takeda Pharmaceutical Company, IND, RTI Surgical, Investment, NuVasive, Market development, Patient, ALS, PVT, COVID-19, Stem cell, Master of ceremonies, US FDA, Technical, Cancer, Pulse, RESEARCH, Growth, Embryonic stem cell, Ethics, Adipose tissue, Silk, Veterinary medicine, Pharmaceutical industry

The global stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources.

Key Points: 
  • The global stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources.
  • Stem Cell Therapy Market Dynamics:
    Key Market Players of Stem Cell Therapy Industry:
    The stem cell therapy market is competitive, with a small number of players competing for market shares.
  • Stem Cell Therapy Market - Key Benefits of Buying the Report:
    The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy market and its subsegments.
  • The report provides insights on the following pointers:
    Analysis of key drivers (Increased funding for stem cell research, rise in collabrations and partnerships is likley to uplift the market growth, Increasing clinical trials for stem cell based-therapies), restraints ( Ethical concerns related to embryonic stem cells, high cost of cell-based research), opportunities (The emergence of iPSCs as an alternative to ESCs, growing demand for stem cell and gene therapy) and challenges (Technical limitations) are influencing the growth of stem cell therapy market.

Stem cell banking market to grow by USD 8.23 billion from 2023 to 2028; North America to account for 41% of market growth- Technavio

Retrieved on: 
Monday, December 11, 2023
Diet, B cell, Brain, Conditional sentence, PerkinElmer, Therapy, International, ROW, Tissue, Cell, Research, Heart, Kidney, USD, Stem cell, Chronic condition, Cancer, Geography, Death, Disability, Fujifilm Corp. v. Benun, Growth, Cell division, Mobile phone, Retail

NEW YORK, Dec. 11, 2023 /PRNewswire/ -- The stem cell banking market size is expected to grow by USD 8.23 billion from 2023 to 2028.

Key Points: 
  • NEW YORK, Dec. 11, 2023 /PRNewswire/ -- The stem cell banking market size is expected to grow by USD 8.23 billion from 2023 to 2028.
  • The market has segmented by product type (adult stem cells, umbilical cord blood stem cells, and embryonic stem cells), type (private and public), and geography (North America, Europe, Asia, and Rest of World (ROW)).
  • This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment.
  • The adult stem cell banking segment leads the market owing to the easy availability of these cells within the human body.

Appia Bio to Present Data on API-192 at the 65th American Society for Hematology Annual Meeting and Exposition

Retrieved on: 
Tuesday, December 5, 2023
Malignancy, Research, Non-Hodgkin lymphoma, Canadian Aviation Regulations, ASH, Health, HSC, IND, Gold, Patient, LOS, ACUA, Cancer, Society, Stem cell, Lymphoma, Pharmaceutical industry, Kite

LOS ANGELES, Dec. 5, 2023 /PRNewswire/ -- Appia Bio, Inc., a biotechnology company developing allogeneic chimeric antigen receptor (CAR)-engineered invariant natural killer T (CAR-NKT) cell therapies from hematopoietic stem cells (HSCs) for patients with cancer, today announced that it will present preclinical data on API-192, a first-in-class CAR-NKT allogeneic cell therapy for the treatment of a broad array of B-cell mediated malignancies including non-Hodgkin lymphoma, one of the most common cancers in the U.S.

Key Points: 
  • These data will be delivered in a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023 in San Diego, CA.
  • API-192 is the first development candidate out of a 2021 collaboration and license agreement between Appia Bio and Kite, a Gilead Company.
  • Under the terms of the agreement, Appia Bio is responsible for preclinical and early clinical research of HSC-derived CAR-NKT product candidates engineered with CARs provided by Kite.
  • "It has been a fantastic team effort to bring API-192 forward as our first development candidate out of our ACUA technology platform.

Supercell Acquires Exclusive Licensing from Japanese Immunotherapy Leader for Advanced NK Cell Treatment Technology

Retrieved on: 
Monday, December 4, 2023
Immune system, CD16, AIET, Stem cell, Patient, Multimedia, Regenerative medicine, CD56, Biotechnology, Supercell, NHS, PMID, Trial of the century, Cancer, Colorectal cancer, Cell, Face, NK, Vaccine, Pharmaceutical industry, Fertilizer

Supercell, through partnerships in regenerative medicine, has secured an exclusive license for a Japanese-developed natural killer (NK) cell culture technique.

Key Points: 
  • Supercell, through partnerships in regenerative medicine, has secured an exclusive license for a Japanese-developed natural killer (NK) cell culture technique.
  • The technique, pivotal in cancer cell elimination and immune system enhancement, will be showcased at the expo, highlighting their latest experimental advancements[1].
  • Dr. Hiroshi Terunuma, a distinguished international authority in cancer treatment based in Japan and a long-standing partner of Supercell, has successfully administered NK cell therapy in over 40,000 cases.
  • In a clinical study, 63 patients diagnosed with terminal malignant pancreatic cancer received conventional cancer therapy supplemented by NK cell infusion.

The Institute of Human Genetics, Polish Academy of Sciences (IHG PAS) is Live on SOPHiA GENETICS

Retrieved on: 
Friday, November 17, 2023
Genetics, Research, Fertility, Disorder, WES, Assistant professor, History, Stem cell, Database, Male, Sophia Genetics, Intelligence, Infertility, Comprehension, IHG, NGS, Polish Academy of Sciences, Reproductive biology, GENETICS, Birth control

BOSTON and ROLLE, Switzerland, Nov. 17, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that the Institute of Human Genetics, Polish Academy of Sciences (IHG PAS), the leading center for genetics research in Poland, is now live on the SOPHiA DDM™ Platform. IHG PAS will use SOPHiA GENETICS to advance its research into rare disorders, in particular male fertility.

Key Points: 
  • BOSTON and ROLLE, Switzerland, Nov. 17, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that the Institute of Human Genetics, Polish Academy of Sciences (IHG PAS), the leading center for genetics research in Poland, is now live on the SOPHiA DDM™ Platform.
  • IHG PAS will use SOPHiA GENETICS to advance its research into rare disorders, in particular male fertility.
  • Using the SOPHiA DDM™ Platform, IHG PAS will have analyzed results and streamlined insights in an efficient timeframe.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on X , LinkedIn , Facebook , and Instagram .

The Institute of Human Genetics, Polish Academy of Sciences (IHG PAS) is Live on SOPHiA GENETICS

Retrieved on: 
Friday, November 17, 2023
Genetics, Research, Fertility, Disorder, WES, Assistant professor, History, Stem cell, Database, Male, Sophia Genetics, Intelligence, Infertility, Comprehension, IHG, NGS, Polish Academy of Sciences, Reproductive biology, GENETICS, Birth control

BOSTON and ROLLE, Switzerland, Nov. 17, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that the Institute of Human Genetics, Polish Academy of Sciences (IHG PAS), the leading center for genetics research in Poland, is now live on the SOPHiA DDM™ Platform. IHG PAS will use SOPHiA GENETICS to advance its research into rare disorders, in particular male fertility.

Key Points: 
  • BOSTON and ROLLE, Switzerland, Nov. 17, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that the Institute of Human Genetics, Polish Academy of Sciences (IHG PAS), the leading center for genetics research in Poland, is now live on the SOPHiA DDM™ Platform.
  • IHG PAS will use SOPHiA GENETICS to advance its research into rare disorders, in particular male fertility.
  • Using the SOPHiA DDM™ Platform, IHG PAS will have analyzed results and streamlined insights in an efficient timeframe.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on X , LinkedIn , Facebook , and Instagram .

Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates

Retrieved on: 
Wednesday, November 8, 2023
Stem cell, Research, Insurance, CAR, Lymphoma, Patent, Leukemia, Bone marrow, Contingency, HIP, CTA, GAAP, SANA, Development, ASH, Biotechnology, Research and development, Transplant, Depreciation, Lymphoid leukemia, IST, Patient, Administration, Immunosuppression, Letter, State Administrative Expenses, Vaccine, Pharmaceutical industry, Commercial property, Cryptocurrency, Reinsurance, IND

Enrollment in the ARDENT Phase 1 study continues, and initial clinical data are expected in 2023 and more robust data expected in 2024.

Key Points: 
  • Enrollment in the ARDENT Phase 1 study continues, and initial clinical data are expected in 2023 and more robust data expected in 2024.
  • Initial HIP proof of concept data are expected in 2023 and 2024.
  • Sana is developing SC451, a hypoimmune-modified stem-cell derived pancreatic islet cell therapy for patients with type 1 diabetes.
  • A discussion of non-GAAP measures, including a reconciliation of GAAP and non-GAAP measures, is presented below under “Non-GAAP Financial Measures.”